Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica
View original at finance.yahoo.com“This momentum continued into the fourth quarter, where sales reached EUR 3,458 million (USD 3,800 million).”
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
North America dominated the global market, accounting for the largest share of 47% in 2025
80% confidenceThe market is bifurcating, with innovation focused on severe phenotypes and smart delivery, while policy shifts mandate affordability for mass-market generic access
80% confidenceAsthma accounts for 1.4 million emergency department visits and 94,000 hospital inpatient stays annually in the US
80% confidenceThe direct cost of asthma care is estimated at USD 3,728 per person annually
80% confidence3,517 asthma deaths were reported in the most recent US data
80% confidenceHigh-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers
80% confidenceIndia reports 34 million asthma cases, creating massive demand for affordable generic inhalers
80% confidenceThe global smart inhaler market was valued at USD 1.53 billion in 2024 and could reach USD 7.9 billion by 2030
80% confidenceChina's Volume-Based Procurement (VBP) has slashed generic prices by ~50%, forcing multinationals to abandon legacy generic margins in favor of introducing innovative biologics to the self-pay and private insurance tiers
80% confidenceThe FDA approved 50 novel drugs in 2024
80% confidenceThe global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a CAGR of 4.50% during the forecast period 2026–2035
80% confidenceThere are 4.7 million children with asthma in the US, contributing to a total affected population of 24.9 million
80% confidence